Direct Answer
Regeneron Pharmaceuticals is a fully integrated biopharmaceutical company best known for Dupixent (dupilumab), one of the most commercially successful biologic drugs ever launched, and Eylea (aflibercept) for eye disease. The company's VelociSuite antibody discovery platform provides a structural R&D advantage. Dupixent's expanding indications in type 2 inflammatory diseases are driving multi-year revenue growth, while Eylea faces biosimilar competition offset partially by the high-dose Eylea HD product.
Company snapshot
| Field | Detail |
|---|---|
| Company | Regeneron Pharmaceuticals, Inc. |
| Ticker | REGN |
| Exchange | Nasdaq |
| Index | S&P 500, Nasdaq-100, Wilshire 5000 |
| Sector | Health Care |
| Industry | Biotechnology |
| Headquarters | Tarrytown, New York, United States |
| Founded | 1988 |
| Fiscal year end | December 31 |
| SEC CIK | 0000872589 |
What Regeneron does
Regeneron Pharmaceuticals is a science-led biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines. Unlike many biotechnology companies that rely on partnerships for all commercialization, Regeneron has built end-to-end capabilities from drug discovery through large-scale manufacturing and sales force deployment.
Dupixent (dupilumab) is Regeneron's primary commercial asset and one of the most important drugs in modern immunology. It is a fully human monoclonal antibody that blocks interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling, the central drivers of type 2 inflammation. Approved indications include moderate-to-severe atopic dermatitis (eczema), moderate-to-severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and COPD with type 2 inflammation. Dupixent is commercialized globally through a 50/50 collaboration with Sanofi; Sanofi records the global sales and the two companies share profits equally after expense reimbursements.
Eylea (aflibercept 2mg) is an anti-VEGF agent injected into the eye for wet age-related macular degeneration, diabetic macular edema, and related conditions. Regeneron holds U.S. commercialization rights; Bayer has ex-U.S. rights. Eylea has faced biosimilar competition in the U.S. since 2023. Regeneron launched Eylea HD (8mg high-dose aflibercept) with FDA approval in 2023, offering a two-monthly and quarterly dosing option that requires fewer office visits than the monthly or every-other-month dosing of Eylea 2mg.
The pipeline includes oncology antibodies (Libtayo/cemiplimab in skin cancers and lung cancer, co-developed with Sanofi), cardiovascular (Praluent/alirocumab, a PCSK9 inhibitor for LDL reduction), and a deep early-to-late-stage pipeline of bispecific antibodies, antibody cocktails, and RNA medicines developed from the VelociSuite platform.
Dupixent franchise economics
Dupixent's commercial trajectory has been exceptional by any pharmaceutical benchmark. From approval in 2017, global net sales have grown to more than $10 billion annually, making it one of the fastest drugs in history to reach blockbuster status. The expansion of indications has extended the addressable market beyond atopic dermatitis (the original approved use) to multiple type 2 inflammatory conditions, with ongoing clinical development targeting additional indications including bullous pemphigoid and chronic spontaneous urticaria.
Under the Sanofi collaboration, Sanofi leads global commercialization and records all Dupixent sales. Regeneron receives a share of profits after reimbursement of commercialization expenses. The accounting treatment means Regeneron's reported revenues do not include Dupixent global sales directly; instead, Regeneron reports "collaboration revenue" from Sanofi reflecting its profit share. The structure creates an accounting mismatch that makes Regeneron's revenues appear smaller than its economic contribution from the drug warrants. Investors need to track Sanofi's disclosed Dupixent global sales and the collaboration cash flows, not just Regeneron's reported revenue line, to fully understand the drug's contribution.
The VelociSuite platform
VelociSuite is Regeneron's proprietary set of genetically engineered mouse and genomics platforms that provide a structural advantage in antibody drug discovery. The foundational technology, VelocImmune, replaces the variable regions of mouse immunoglobulin genes with the human equivalents. When these mice are immunized against a target antigen, they generate fully human antibody sequences, eliminating the humanization engineering step that adds time, cost, and sometimes immunogenicity to antibodies generated in standard mice.
VelocImmune was the technology that generated the antibody sequences for Dupixent, Eylea, Kevzara, REGEN-COV, and Libtayo, among others. The speed advantage compounds over time: Regeneron can move from target identification to clinical candidate in a shorter cycle than competitors relying on humanization steps, giving it a pipeline density advantage per unit of R&D investment.
Risks and watchlist
- Dupixent concentration: The vast majority of Regeneron's near-term earnings power derives from Dupixent. Any unexpected safety signal, competing biologic (IL-13-specific agents, OX40 pathway inhibitors), or government pricing pressure would have an outsized impact on the investment case.
- Eylea biosimilar erosion: Biosimilars entering the U.S. Eylea market are eroding revenue. Eylea HD adoption rate versus biosimilar share loss determines the net impact on Eylea revenue over the next several years.
- Drug pricing policy: The Inflation Reduction Act's Medicare drug price negotiation provisions create potential for government-set pricing on high-volume, large-revenue drugs. Dupixent's scale makes it a potential future negotiation target.
- Pipeline execution: Long-term growth beyond Dupixent and Eylea depends on pipeline success. Late-stage clinical trial failures are common in biopharmaceuticals and can result in significant write-offs and stock declines.
- Sanofi collaboration dependency: A significant portion of Regeneron's revenue and profits flows through the Sanofi collaboration agreement. Any change in the relationship, renegotiation of terms, or Sanofi's strategic decisions would affect Regeneron's reported results.
Frequently asked questions
What does Regeneron Pharmaceuticals do?
Regeneron Pharmaceuticals is a fully integrated biopharmaceutical company focused on developing medicines for serious diseases using monoclonal antibodies and other biotechnology platforms. Its commercialized products include Dupixent (dupilumab) for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and other type 2 inflammatory conditions; Eylea (aflibercept) for wet age-related macular degeneration and diabetic macular edema; and Kevzara and REGEN-COV. Dupixent, co-developed and co-commercialized with Sanofi, has become one of the most successful biologic drug launches in pharmaceutical history.
How does Regeneron make money?
Regeneron generates revenue primarily from two sources: collaboration revenue from its partnership with Sanofi (which includes Dupixent profits split and reimbursement of development costs) and net product sales of Eylea in the U.S. Dupixent is the dominant revenue driver; its global sales (recognized by Sanofi, with Regeneron receiving a collaboration payment) have grown from launch to more than $10 billion annually. Eylea revenue comes from U.S. net product sales; in most international markets, Bayer holds the rights and pays royalties to Regeneron. The company also has revenue from its Veloce discovery platform collaborations and government contracts.
What is the VelociSuite platform and why is it important?
VelociSuite is Regeneron's proprietary set of genetically engineered mouse technologies that accelerate the discovery and development of fully human antibody medicines. The core component, VelocImmune, replaces the mouse immune system's antibody-producing genes with the human equivalents, allowing the mouse to produce human antibodies against target proteins. This platform has dramatically reduced the time and cost of taking an antibody drug from target identification to clinical candidate stage. VelociSuite is the foundational technology behind most of Regeneron's clinical pipeline and its key strategic differentiator: it enables Regeneron to generate candidates faster and with higher initial human compatibility than many traditional approaches.
What are the risks from Eylea biosimilar competition?
Eylea (aflibercept) was one of Regeneron's two major revenue drivers, contributing meaningful net product sales from U.S. distribution rights. Biosimilar competition to Eylea began entering the U.S. market in 2023 and 2024, creating price pressure on the original product. Regeneron developed Eylea HD (high-dose aflibercept, 8mg), which requires fewer injections and was approved in 2023, as a next-generation product designed to capture patients on less frequent dosing schedules. The pace of Eylea HD adoption versus erosion from Eylea biosimilars is a key financial variable; if Eylea HD captures treating physicians' preference for new starts, the transition preserves much of the revenue base. If biosimilars aggressively capture market share, Eylea revenue declines faster.
What are the main risks for Regeneron investors to watch?
Key risks include Dupixent concentration (the vast majority of Regeneron's near-term earnings power derives from Dupixent; any unexpected safety signal, competitive biologic entrant, or pricing pressure would have an outsized impact), Eylea biosimilar erosion (biosimilars are reducing the revenue contribution from Eylea, and the pace of Eylea HD adoption determines how much is preserved), pipeline dependency (long-term growth requires pipeline programs succeeding in late-stage trials; pipeline failures are common in biopharmaceuticals and can result in significant R&D write-offs), drug pricing policy (U.S. government drug pricing negotiations under the Inflation Reduction Act could reduce future pricing power for Dupixent and other large-volume branded drugs), and the Sanofi collaboration structure (Dupixent economics depend on the collaboration agreement terms; any renegotiation or change in the relationship would affect reported financial results).